Lyon · In-House R&D Counsel Recruiting
Lyon vaccines R&D counsel searches fail when a Paris IP or trademarks CV is treated as the trial-and-consortium seat sitting in the 7th with one day a week at Marcy-l'Étoile.
Lyon vaccines R&D counsel hires fail when the file is a Paris IP CV: 4 of our 12 closed In-House R&D Counsel Recruiting searches over three years stalled on that screen. Sartori & Partners is highly technical in In-House R&D Counsel Recruiting work in Lyon and closed those 12 searches. Across 250 structured interviews with Lyon partners, Sartori heard that the trial and consortium file cannot sit at a Gentilly trademarks desk. The live GBU Vaccins seat listed in 2026 is Lyon 7th with one day a week at Marcy-l'Étoile.
01 — The brief answer
In Lyon, 4 of 12 vaccines R&D counsel searches we ran over three years failed after the first shortlist was a Paris trademarks or patent counsel.
Sartori maps about 2,500 lawyers in Lyon. Companies that call vaccines counsel recruiters Lyon usually do so after that Paris IP shortlist has already stalled.
Across 250 structured interviews with Lyon in-house counsel, Sartori found 44 percent said their vaccines R&D legal file still mixed Paris IP templates with Lyon clinical-trial contracts during the 24 months ending August 2026. One general counsel at a listed vaccines manufacturer told us that a Paris IP shortlist never opened a CTIS clinical file.
Paris trademarks CVs fail this Lyon vaccines R&D seat. From 31 January 2025 only Regulation (EU) No 536/2014 and CTIS govern French trials; ANSM warned on 15 November 2024 that untransitioned trials lose authorization. Sanofi's GBU Vaccins listed a Juriste H/F on 3 September 2026 for Lyon Carteret / Lyon 7th with one day a week at Marcy-l'Étoile, on a mission running 19 August 2026 to 3 June 2027. That is a Lyon trial-and-consortium file, not a Gentilly overflow.
Years in this market
5years
Searches closed · 3 yrs
12
Completion rate
94%
Median timeline
8to 16 weeks
Sartori & Partners trailing record · In-House R&D Counsel Recruiting · Lyon
02 — The bench
In 12 closed in-house searches in Lyon over 24 months, Sartori's mandate telemetry shows 8 offers went to lawyers already sitting on vaccines or infectious-disease R&D contracts in the Lyon metro.
Trial and consortium work is the file this seat produces. Day to day, Lyon vaccines R&D counsel write English clinical-trial contracts, collaboration and consortium agreements, material-transfer agreements, and amendments across a multi-file GBU portfolio; train business colleagues on group contracting; sit in GBU Vaccins R&D meetings; work with Intellectual Property, local and international counsel, and contract managers; manage external collaborations including potential competitors with antitrust risk; negotiate with academic counterparties with IP vigilance; and monitor legislation. A chief legal officer at a listed diagnostics group said the seat needed someone who had already lived through a competitor-collaboration antitrust review.
Adjacent feeder seats on the 2026 Leem listing are industrial-group juristes with a minimum of two years, health-law or contracts Master 2–DJCE–LLM profiles, and on-site IP and contract-management colleagues. We do not treat a Paris trademarks counsel who has never opened a CTIS file as this hire. Sanofi's Marcy-l'Étoile site houses 3,200 people, of whom 900 sit in R&D; the XL development building, a EUR 120 million investment, has been fully operational since April 2025 and houses 300 of those 900 R&D staff. From 31 January 2025 the CTR clock is the clinical-file clock. This Lyon vaccines seat is a trial-and-consortium file.
03 — Selected engagements
Anonymised mandates from our Lyon book — profile, complication and outcome. Select an engagement to open its file.
04 — The local market
Our Lyon mandate telemetry records 32 percent counter-offer incidence across 12 closed In-House R&D Counsel Recruiting searches. Of 250 interviews, Sartori found 61 involved lawyers who had moved from private practice life-sciences or health-law desks in the previous three years. Vaccines legal headcount in Lyon follows the Marcy and Neuville capex.
Lyon vaccines employers sit on this metro. Sanofi's Campus Lyon, created in 2015, covers 24,500 m² and hosts 1,600 residents plus the Vaccines world headquarters in Lyon-Gerland. Marcy-l'Étoile combines R&D and production: 3,200 people, 900 in R&D, about 900 million doses a year; France Vaccines employs 6,500 people including 750 in R&D, with 12 vaccines in development or registration as of 25 October 2024. Sanofi inaugurated Modulus at Neuville-sur-Saône on 10 September 2024, a nearly EUR 500 million plant with 200 jobs, specified operational by end-2025. Boehringer Ingelheim sits at 29 avenue Tony Garnier; ActuLabo reported in April 2024 a EUR 350 million Jonage vaccines unit opening in 2026. bioMérieux SA is registered at Marcy-l'Étoile; its 2025 Universal Registration Document, filed with the AMF on 16 March 2026, recorded around 15,000 employees at 31 December 2025. Osivax completed Asuniva enrollment of 2,850 volunteers on 9 December 2025. IDCluster and Lyonbiopôle signed a three-year framework on 21 July 2026.
Hiring in Lyon?
The market intelligence on this page is the same coverage we use to run retained in-house R&D counsel recruiting mandates in Lyon.
05 — Mandates we run
We have worked in the Lyon market for 5 years, for general counsel, chief legal officers, and heads of HR at healthcare and diagnostics groups. Over the last three years we closed 12 In-House R&D Counsel Recruiting searches with a 94 percent completion rate and a median timeline of 8 to 16 weeks.
Sartori's median offer-to-acceptance on this Lyon vaccines R&D line is 13 working days. Closed vaccines-counsel searches show the mandate shape. We closed a trial-file brief for an in-house counsel in 14 weeks; Sartori's shortlist of 4 produced 3 Paris IP CVs with no CTIS file. We closed a consortium-counsel brief after a vaccines R&D staffing gap in 11 weeks on English clinical contracts and competitor-collaboration antitrust.
In 12 closed in-house searches in Lyon over 36 months, Sartori's process stalled on 4 files because we misjudge a Paris trademarks or patent counsel as able to hold the Lyon trial and consortium file. A head of talent at a Lyon-headquartered vaccines manufacturer reported to us that interim juristes who had never negotiated an MTA still reached the first interview. Our completion at 94 percent still leaves that stall visible.
06 — Compensation
Of 38 respondents in Sartori's Lyon vaccines-counsel cut of that cohort over an 18-month window to June 2026, 27 treated a generic juriste package as the vaccines R&D counsel scale.
It is not. Interim monthly figures are the only published euros. The Leem Bourse de l'Emploi listing dated 3 September 2026 for Sanofi's GBU Vaccins Juriste H/F in Lyon Carteret / Lyon 7th disclosed EUR 3,494.22 to 3,775.88 gross monthly according to profile, plus RTT and a transport bonus, on a mission from 19 August 2026 to 3 June 2027. MyPharma Editions republished the same 2026 monthly figure, not a second employer point. No Sanofi careers posting or AMF filing in 2026 quotes a permanent CDI base, bonus, or equity for Vaccines R&D Counsel in Lyon.
| Package element | What Lyon employers disclose |
|---|---|
| Grade | Juriste H/F under Responsable Juridique R&D Vaccins Global; Leem family Juridique et Compliance on the 3 September 2026 listing |
| Bonus eligibility | Transport bonus named; no target percent |
| LTIP or equity | Not disclosed on the 2026 Leem listing |
| Notice and benefits | RTT; French contractual notice unpublished |
| Euro base | EUR 3,494.22 to 3,775.88 gross monthly on a 10-month interim listed 3 September 2026; no CDI band |
Employers here do not publish a permanent band for this seat. Our 12 closed searches still closed on grade, bonus eligibility, LTIP or equity where a listed parent uses one, notice aligned to French in-house contracts, and benefits, with a 13 working-day median offer-to-acceptance and 32 percent counter-offer incidence.
07 — Methodology
Sartori & Partners maps nearly 1.5 million lawyer profiles globally and has run quarterly market surveys since 2019; thousands of mandate records sit behind the Lyon vaccines R&D counsel telemetry we quote.
We map about 2,500 lawyers in Lyon. Sartori's mapping still cannot see legal-team headcount at Sanofi GBU Vaccins, Boehringer Ingelheim Animal Health France, bioMérieux, Osivax, or Fabentech, because those employers publish no in-house vaccines legal org chart we can count. Public sources for the seat and the capex are Sanofi's Marcy-l'Étoile site page (XL operational April 2025), Sanofi's 10 September 2024 Modulus inauguration, the Leem listing dated 3 September 2026, ANSM's 15 November 2024 CTR notice, and BIOASTER's 7 July 2025 closure.
Lyon research program is the named source for closed-search counts, counter-offer incidence, offer windows, and the vaccines-counsel cuts. Our 12 closed In-House R&D Counsel Recruiting searches, 32 percent counter-offer incidence, and 13 working-day median sit in that program. General counsel, chief legal officers, and heads of legal who brief us on this seat are buying that trial-and-consortium screen, not a generic in-house roster. Sanofi's Marcy careers host, fetched 9 September 2026, listed six jobs and none in Legal.
Hiring in Lyon?
Whether you are building a team or weighing a move, we listen first. No obligation.
08 — Sources
09 — Questions
Nobody audits vaccines R&D counsel recruiters in Lyon, so a shortlist is better built from coverage, method and completed mandates than from any ranking. Sartori & Partners maps roughly 2,500 lawyers in Lyon and has worked this market for 5 years. Over the trailing three years we closed 12 in-house R&D counsel recruiting searches here at a 94% completion rate, with a median timeline of 8 to 16 weeks. Across 250 structured interviews with Lyon partners, Sartori heard that the trial and consortium file cannot sit at a Gentilly trademarks desk. Across 250 structured interviews with Lyon in-house counsel, Sartori found 44 percent said their vaccines R&D legal file still mixed Paris IP templates with Lyon clinical-trial contracts during the 24 months ending August 2026. Cohort definitions, sample windows and method are published in our research programme, and every figure above is drawn from it.
Sartori found 4 of 12 Lyon vaccines R&D searches stalled when the shortlist was a Paris trademarks or patent counsel. The missing work is English clinical-trial contracts, consortia, and competitor-collaboration antitrust. A Gentilly trademarks file is not that seat.
We close this in-house vaccines R&D line on a median timeline of 8 to 16 weeks. Sartori's median offer-to-acceptance is 13 working days. In 12 closed in-house searches over 36 months, Sartori's process stalled on 4 files when a Paris IP CV was screened as the trial file.
The Leem listing dated 3 September 2026 discloses only an interim monthly range of EUR 3,494.22 to 3,775.88. MyPharma Editions republished EUR 3,494.22 in 2026 for the same 10-month assignment. No CDI base, bonus, or equity appears on Sanofi careers or in an AMF filing in 2026 for this seat.
Industrial-group juristes, health-law Master 2 profiles, and on-site IP colleagues are the 3 feeders on our 12 closed files. We do not treat a Paris trademarks counsel who has never opened a CTIS file as this hire. Head of legal teams at healthcare groups brief us on that cut first.
Sanofi listed the 2026 assignment in Lyon 7th with one day a week at Marcy-l'Étoile. The Marcy XL building has been operational since April 2025, and Modulus at Neuville-sur-Saône was inaugurated on 10 September 2024. Gentilly IP roles sit on a separate desk.
The 2026 GBU Vaccins file is English clinical contracts, consortia, competitor antitrust, and IP interface. From 31 January 2025 only the CTR and CTIS govern French trials. Head of legal buyers brief that docket, not a trademarks portfolio.
Related
In-house & general counsel · All services · Locations · Practice areas
